Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Eir
  6. /
  7. Lantech Pharmaceuticals Ltd.
EIR
•Lantech Pharmaceuticals Ltd.•March 15, 2019

Lantech Pharmaceuticals Ltd. – FDA EIR, Mar 15, 2019

Record Details

An FDA "For Cause" inspection of Lantech Pharmaceuticals Limited in Andhra Pradesh, India, was conducted from March 6 to March 15, 2019. The inspection focused on the company's solvent recovery operations due to its implication as a potential source of N-nitrosamine (NDMA and NDEA) contamination in Active Pharmaceutical Ingredients (APIs) such as Valsartan, Telmisartan, and Lamivudine. The inspection adhered to Compliance Program 7356.002F and ICH Q7 guidelines. The inspection revealed nine significant observations, indicating a failure to fully correct issues from a previous April 2018 inspection. Primary violations included inadequate investigations into nitrosamine contamination, specifically failing to evaluate all potential root causes, consider NDMA, or assess cross-contamination risks across different APIs and shared equipment. Other critical issues identified were inadequate equipment cleaning, insufficient control over electronic Quality Control laboratory data, lack of Quality Unit oversight, and absence of process validation for solvent recovery. Furthermore, corrective and preventive actions were not consistently documented, production equipment storage was inappropriate, and solvent status was not properly identified. Management, led by Mr. V. Prakash Reddy, acknowledged these deficiencies and committed to corrections, promising a written response to the Agency within 15 United States business days.

Company
Lantech Pharmaceuticals Ltd.
Inspection date
March 15, 2019
Product type
drugs
Office
Office of Regulatory Affairs
People
  • Dipesh K. Shah
  • Tenzin Jangchup (Performance Improvement Coordinator)
  • Eric Dong (investigator)
View Company Profile

ID · 9baa12b0-cd0f-4fd8-af80-66a54154c688

Violation Codes3
21 CFR 820.3021 CFR 21121 CFR 820.100

Full citation text and observation details available on the Dashboard.

Other documents for Lantech Pharmaceuticals Ltd.
  • 483 - 2019-03-15March 15, 2019

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Lantech Pharmaceuticals Ltd.
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.